CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
pegaptanib sodiumdrug
Likely dose
Pegaptanib sodium 1 drop per dosed eye per protocolAI-extracted
Key inclusion· 1
  • ✓Completion of the preceding study A5751010
Key exclusion· 2
  • ✕Serious heart, kidney, and/or liver disease
  • ✕Diabetic retinopathy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00239928
NCT00239928Phase 2Completed
CompareCT.gov

Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration (Extension Study From A5751010)

Pfizer·interventional·Posted Oct 17, 2005·Updated May 12, 2011

In Brief

A Phase 2 clinical trial evaluating pegaptanib sodium for Macular Degeneration. Completed, enrolled 61 participants across 12 sites.

Detailed Summary

This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 17, 2005
Enrollment StartSep 1, 2005
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.7 years ago

Interventions

pegaptanib sodiumdrug

1 drop per dosed eye per protocol.